The article by Rubin et al. (1) is of great interest, because it clearly demonstrates the high risk of diabetes mellitus (DM) development in women with polycystic ovary syndrome (PCOS) compared with their healthy peers. Specifically, it was shown that DM occurrence is higher in women with PCOS, and, among other factors, increased body mass index (BMI) and insulin resistance (IR), but not age, are positively associated with this phenomenon. Additionally, the subjects who developed DM were significantly more obese than those who remained euglycemic. However, the percentage of lean women with PCOS who developed DM during the follow-up period is not provided, which is crucial information. Because the coexistence of B-cell dysfunction and IR is a prerequisite for DM occurrence, it is obvious that ameliorating IR will decrease the risk. Indeed, we have recently demonstrated in a cross-sectional study of 1345 women with PCOS that IR increases with aging only in obese and not in lean and overweight women with PCOS (2). Furthermore, in their long-term prospective study Gambineri et al. (3) reported that in lean women with PCOS the risk for DM development is comparable to that among their normal peers. Meanwhile, a critical analysis of the available studies shows that DM development risk is higher in obese women with PCOS than in their lean counterparts (Table 1) (4–12). Table 1. Evolution to Diabetes and Impaired Glucose Tolerance in PCOS, Available Literature Data Author, Year n BMI, kg/m2 Follow-Up, y Evolution to Impaired Glucose Tolerance Evolution to DM Insulin Levels Ehrmann, 1999 25 41 2.4 40% N/A N/A Pasquali, 1999 21 32 10 N/A Deterioration Norman, 2001 67 35 to 41 6 9.3% 7.4% N/A 27 to 28 0 0 N/A Elting, 2001 34 24 15 N/A 2% Stable Legro, 2005 35 35 3 16% N/A Stable Brown, 2011 172 26 2.6 0% 0% Stable 82 26 5.5 0% 0% Stable Hudecova, 2011 84 ? 14 9.5% 8.3% Ν/Α Schmidt, 2011 35 27.1 21 0% 0% Stable Carmina, 2013 118 27 20 N/A N/A Stable Rubin, 2017 1162 32.3 11.1 N/A 9/1000 person-years, OR 4 N/A Rubin, 2017 18,477 N/A 11.1 N/A 8/1000 person-years, OR 4 N/A Gambineri, 2012 249 16.9 Total group 39% N/A <25 Incidence rate × 100 person-years 0.25 N/A 25 to 30 0.63 N/A >30 2.02 N/A Author, Year n BMI, kg/m2 Follow-Up, y Evolution to Impaired Glucose Tolerance Evolution to DM Insulin Levels Ehrmann, 1999 25 41 2.4 40% N/A N/A Pasquali, 1999 21 32 10 N/A Deterioration Norman, 2001 67 35 to 41 6 9.3% 7.4% N/A 27 to 28 0 0 N/A Elting, 2001 34 24 15 N/A 2% Stable Legro, 2005 35 35 3 16% N/A Stable Brown, 2011 172 26 2.6 0% 0% Stable 82 26 5.5 0% 0% Stable Hudecova, 2011 84 ? 14 9.5% 8.3% Ν/Α Schmidt, 2011 35 27.1 21 0% 0% Stable Carmina, 2013 118 27 20 N/A N/A Stable Rubin, 2017 1162 32.3 11.1 N/A 9/1000 person-years, OR 4 N/A Rubin, 2017 18,477 N/A 11.1 N/A 8/1000 person-years, OR 4 N/A Gambineri, 2012 249 16.9 Total group 39% N/A <25 Incidence rate × 100 person-years 0.25 N/A 25 to 30 0.63 N/A >30 2.02 N/A Abbreviations: N/A, not applicable; OR, odds ratio. View Large It should be borne in mind that although lean women with PCOS have intrinsic IR, a cardinal characteristic of the syndrome, the degree of IR is comparable to that of their obese control peers (13). Hence, obesity per se could well be the critical risk factor for IR development, and it may be hypothesized that DM occurrence in women with PCOS is in fact an epiphenomenon due to an increased BMI, because obesity and PCOS usually coincide (14). Given that BMI and androgen excess are positively associated with IR and androgens decline through time, it appears that if women with PCOS do not become obese, they are likely to have a better metabolic profile during their reproductive years. Accordingly, we should not label all women with PCOS as being at high risk for DM, but only those who remain obese through the years. Last but not least, one of the major tasks of the caring physician should be to persistently encourage a healthy lifestyle and weight reduction to minimize DM risk and gain better metabolic control. Acknowledgments Disclosure Summary: The author has nothing to disclose. Abbreviations: BMI body mass index DM diabetes mellitus IR insulin resistance PCOS polycystic ovary syndrome. References 1. Rubin KH, Glintborg D, Nybo M, Abrahamsen B, Andersen M. Development and risk factors of type 2 diabetes in a nationwide population of women with polycystic ovary syndrome. J Clin Endocrinol Metab . 2017; 102( 10): 3848– 3857. Google Scholar CrossRef Search ADS PubMed 2. Livadas S, Kollias A, Panidis D, Diamanti-Kandarakis E. Diverse impacts of aging on insulin resistance in lean and obese women with polycystic ovary syndrome: evidence from 1345 women with the syndrome. Eur J Endocrinol . 2014; 171( 3): 301– 309. Google Scholar CrossRef Search ADS PubMed 3. Gambineri A, Patton L, Altieri P, Pagotto U, Pizzi C, Manzoli L, Pasquali R. Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study. Diabetes . 2012; 61( 9): 2369– 2374. Google Scholar CrossRef Search ADS PubMed 4. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care . 1999; 22( 1): 141– 146. Google Scholar CrossRef Search ADS PubMed 5. Pasquali R, Gambineri A, Anconetani B, Vicennati V, Colitta D, Caramelli E, Casimirri F, Morselli-Labate AM. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment. Clin Endocrinol (Oxf) . 1999; 50( 4): 517– 527. Google Scholar CrossRef Search ADS PubMed 6. Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod . 2001; 16( 9): 1995– 1998. Google Scholar CrossRef Search ADS PubMed 7. Elting MW, Korsen TJ, Bezemer PD, Schoemaker J. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod . 2001; 16( 3): 555– 560. Google Scholar CrossRef Search ADS 8. Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab . 2005; 90( 6): 3236– 3242. Google Scholar CrossRef Search ADS PubMed 9. Brown ZA, Louwers YV, Fong SL, Valkenburg O, Birnie E, de Jong FH, Fauser BC, Laven JS. The phenotype of polycystic ovary syndrome ameliorates with aging. Fertil Steril . 2011; 96( 5): 1259– 1265. Google Scholar CrossRef Search ADS PubMed 10. Hudecova M, Holte J, Olovsson M, Larsson A, Berne C, Poromaa IS. Diabetes and impaired glucose tolerance in patients with polycystic ovary syndrome—a long term follow-up. Hum Reprod . 2011; 26( 6): 1462– 1468. Google Scholar CrossRef Search ADS PubMed 11. Schmidt J, Landin-Wilhelmsen K, Brännström M, Dahlgren E. Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study. J Clin Endocrinol Metab . 2011; 96( 12): 3794– 3803. Google Scholar CrossRef Search ADS PubMed 12. Carmina E, Campagna AM, Lobo RA. Emergence of ovulatory cycles with aging in women with polycystic ovary syndrome (PCOS) alters the trajectory of cardiovascular and metabolic risk factors. Hum Reprod . 2013; 28( 8): 2245– 2252. Google Scholar CrossRef Search ADS PubMed 13. Stepto NK, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF, Teede HJ. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic–hyperinsulaemic clamp. Hum Reprod . 2013; 28( 3): 777– 784. Google Scholar CrossRef Search ADS PubMed 14. Alvarez-Blasco F, Botella-Carretero JI, San Millán JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med . 2006; 166( 19): 2081– 2086. Google Scholar CrossRef Search ADS PubMed Copyright © 2018 Endocrine Society
Journal of Clinical Endocrinology and Metabolism – Oxford University Press
Published: Jan 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera